ENTITY

Jiangsu Hengrui Pharmaceuticals (1276 HK)

316
Analysis
Health Care • China
Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.
more
•11 Feb 2026 07:54

Aequitas: Wuxi Lead A/H Trading - Weak Retail, Okish Institutional Demand

Wuxi Lead Intelligent Equipmen (300450 CH),  raised around US$725m in its H-share listing. In this note, we talk about the trading dynamics.

Logo
271 Views
Share
•11 Feb 2026 07:30

Wuxi Lead Equipment (470 HK): Almost Fair

​Wuxi Lead Intelligent Equipment's lukewarm IPO response leads to a fair value estimate of HK$45.6-48.8, suggesting it is almost fairly-valued with...

Logo
268 Views
Share
•08 Feb 2026 16:03

Montage Technology H Share Listing (6809 HK): Trading Debut

Montage's international and retail oversubscription rates were significantly above the median of recent large AH listings. The AH discount remains...

Logo
392 Views
Share
•08 Feb 2026 10:15

A-H Premium Weekly (Feb 6th): China Oilfield Services, Huaxin Building Materials

We analyzed A-H premium changes in the past week and highlight A-H premium changes for China Oilfield Services, Huaxin Building Materials, Cngr...

Logo
294 Views
Share
bullish•Muyuan Foods Co
•06 Feb 2026 05:54

Aequitas: Muyuan Foods A/H Trading - Weak Retail and Mediocre Insti Demand

Muyuan Foods Co (2714 HK), a leader in the hog farming industry, raised around US$1.6bn in its H-share listing. In this note, we talk about the...

Logo
225 Views
Share
x